We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Real Time PCR Assays Compared for Viral Quantification

By LabMedica International staff writers
Posted on 14 Jan 2013
The performance of three real time polymerase chain reaction assays has been compared for the quantification of polyomavirus BK.

Reactivation of latent polyomavirus BK is associated with nephropathy (PVAN) after renal transplantation and the BK viral load determinations are a highly sensitive and specific method for predicting risk for PVAN.

At the Albany Medical Center Hospital (NY, USA) a team of investigators collected 100 anticoagulated plasma specimens from 69 renal transplant patients which were analyzed with three real-time PCR (rt-PCR) assays for BK viral load determination. More...
The rt-PCR assays were evaluated in terms of linearity, dynamic range, and accuracy, against a conventional PCR with primers and probe targeting the large T antigen (TOR) (Integrated DNA Technologies, Coralville, IA, USA).

The two commercial rt-PCR assays used were the MultiCode-RTx BK (MC-RTx) virus Analyte Specific Reagents (ASR) from Luminex (Austin, TX, USA), and the MGB-Alert BKV ASR (MGB) from Epoch Biosciences (Princeton, NJ, USA). A laboratory developed assay (LDA) was also evaluated. Of the 100 specimens from 69 patients sent to the laboratory for routine polyomavirus measurements by the TOR and analyzed with all three rt-PCR assays, 76 were defined as true positive for BKV DNA and no samples were inhibitory for PCR.

The MC-RTx assay was positive for all 76 specimens whereas MGB was positive for 64 and LDA was positive for 55. The viral load range for these samples was from1.71 to 7.55 log10 copies/mL, while the median viral load was 3.01 log10 copies/mL. BKV DNA was not detected by any method in the true negative specimens. The sensitivities of the assays was 100% for MC-RTx, 84% for MGB and 72% for LDA and the specificities were 100% for all three assays.

The authors concluded that all three real-time PCR assays are reliable for measuring BKV loads for the identification of patients at risk for PVAN. These assays demonstrated superiority over the TOR with regards to precision. MC-RTx appears to have enhanced sensitivity and better performance among divergent strains of BK. The study was published on December 27, 2012, in the Journal of Clinical Virology.

Related Links:

Albany Medical Center Hospital
Integrated DNA Technologies
Luminex




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.